These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 38680067

  • 21. Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K-CREATE Study.
    Kim JS, Kim BW, Kim JI, Chung WC, Jung SW, Bang CS, Kim GH, Jeon SW, Joo MK, Lee SH, Lim YJ, Sung JK, Seo SY, Park SY, Lee WS, Lee HL, Kim KB, Kim HU.
    Helicobacter; 2024; 29(4):e13126. PubMed ID: 39143948
    [Abstract] [Full Text] [Related]

  • 22. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
    Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Chen CC, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet Infect Dis; 2019 Oct; 19(10):1109-1120. PubMed ID: 31559966
    [Abstract] [Full Text] [Related]

  • 23. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS.
    World J Gastroenterol; 2015 Jan 07; 21(1):351-9. PubMed ID: 25574111
    [Abstract] [Full Text] [Related]

  • 24. A randomised controlled clinical study of standard triple therapy, bismuth-based quadruple therapy and sequential therapy for Helicobacter pylori infection in children.
    Miao R, Chen J, Gao S, Wang L, Zhou W, Wan C, Wang Z.
    BMC Pediatr; 2024 Aug 23; 24(1):543. PubMed ID: 39180014
    [Abstract] [Full Text] [Related]

  • 25. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.
    Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J.
    Am J Gastroenterol; 2003 Mar 23; 98(3):562-7. PubMed ID: 12650788
    [Abstract] [Full Text] [Related]

  • 26. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y.
    Dig Liver Dis; 2016 May 23; 48(5):506-511. PubMed ID: 26847964
    [Abstract] [Full Text] [Related]

  • 27. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.
    Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ.
    Gut Microbes; 2020 Sep 02; 11(5):1314-1323. PubMed ID: 32362221
    [Abstract] [Full Text] [Related]

  • 28. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
    Liou JM, Chen PY, Luo JC, Lee JY, Chen CC, Fang YJ, Yang TH, Chang CY, Bair MJ, Chen MJ, Hsu YC, Hsu WF, Chang CC, Lin JT, Shun CT, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Gastroenterology; 2018 Oct 02; 155(4):1109-1119. PubMed ID: 29964036
    [Abstract] [Full Text] [Related]

  • 29. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
    Chen MJ, Chen PY, Fang YJ, Bair MJ, Chen CC, Chen CC, Yang TH, Lee JY, Yu CC, Kuo CC, Chiu MC, Chou CK, Chen CY, Hu WH, Tsai MH, Hsu YC, Shun CT, Luo JC, Lin JT, El-Omar EM, Wu MS, Liou JM, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet Gastroenterol Hepatol; 2023 Jul 02; 8(7):623-634. PubMed ID: 37178702
    [Abstract] [Full Text] [Related]

  • 30. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H.
    Helicobacter; 2010 Jun 02; 15(3):233-8. PubMed ID: 20557366
    [Abstract] [Full Text] [Related]

  • 31. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F.
    Helicobacter; 2013 Dec 02; 18(6):459-67. PubMed ID: 23714140
    [Abstract] [Full Text] [Related]

  • 32. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, Castro-Fernández M, Antón R, Sacristán B, Cosme A, Barrio J, Harb Y, Gonzalez-Barcenas M, Fernandez-Bermejo M, Algaba A, Marín AC, McNicholl AG, H. pylori Study Group of the Spanish Gastroenterology Association.
    Dig Dis Sci; 2014 Feb 02; 59(2):383-9. PubMed ID: 24126798
    [Abstract] [Full Text] [Related]

  • 33. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H, Zeng Z, Chen S, Liu D, Lv N, the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology.
    Antimicrob Agents Chemother; 2018 Sep 02; 62(9):. PubMed ID: 29914954
    [Abstract] [Full Text] [Related]

  • 34. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ.
    BMC Gastroenterol; 2016 Jul 26; 16(1):79. PubMed ID: 27460100
    [Abstract] [Full Text] [Related]

  • 35. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
    Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ.
    J Dig Dis; 2020 Oct 26; 21(10):549-557. PubMed ID: 32833285
    [Abstract] [Full Text] [Related]

  • 36. Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
    Song Z, Suo B, Tian X, Ren X, Xue Y, Niu Z, Zhou L.
    Dig Liver Dis; 2023 May 26; 55(5):601-607. PubMed ID: 36646526
    [Abstract] [Full Text] [Related]

  • 37. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
    He XJ, Wang XL, Huang XY, Li DZ, Liu G, Wang W, Li DL.
    Clin Res Hepatol Gastroenterol; 2023 Jan 26; 47(1):102052. PubMed ID: 36400418
    [Abstract] [Full Text] [Related]

  • 38. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A.
    Am J Gastroenterol; 2006 Sep 26; 101(9):1985-90. PubMed ID: 16968503
    [Abstract] [Full Text] [Related]

  • 39. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B, Wang J, Li J, Liu L, Chen Y.
    Helicobacter; 2019 Apr 26; 24(2):e12566. PubMed ID: 30780194
    [Abstract] [Full Text] [Related]

  • 40. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D, Almeida N, Gregório C, Cabral JE, Casela A, Donato MM, Tomé L.
    BMC Gastroenterol; 2017 Feb 15; 17(1):31. PubMed ID: 28202013
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.